PSI 5004

Drug Profile

PSI 5004

Alternative Names: PSI-5004; Racemic FTC; Racivir; RCV - Pharmasset

Latest Information Update: 31 Jan 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Emory University
  • Developer Pharmasset
  • Class Antivirals; Dideoxynucleosides; Small molecules
  • Mechanism of Action Nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • Available For Licensing Yes - HIV infections

Highest Development Phases

  • No development reported HIV infections

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 31 Jan 2012 No development reported - Phase-II for HIV infections in Argentina (PO)
  • 31 Jan 2012 No development reported - Phase-II for HIV infections in Mexico (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top